Abstract
Summary
Tumor genomics, also known as cancer genomics, is an emerging sub-discipline in genomics, mainly through the high-throughput sequencing technology to associate genes with cancer. Tumor is a disease caused by the accumulation of DNA mutations that leads to an uncontrolled proliferation of cells and the formation of new organisms. The main goal of tumor genomics is to provide new methods for tumor diagnosis, tumor clinical outcome prediction and tumor target treatment by identifying new oncogenes or tumor suppressor genes.
LPI (LP Information)' newest research report, the “Tumor Genomics Industry Forecast” looks at past sales and reviews total world Tumor Genomics sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Genomics sales for 2023 through 2029. With Tumor Genomics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Genomics industry.
This Insight Report provides a comprehensive analysis of the global Tumor Genomics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Genomics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Genomics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Genomics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Genomics.
The global Tumor Genomics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor Genomics players cover Abbott Laboratories, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Fluidigm Corporation, General Electric Company, Illumina, Inc. and Merck KGaA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Genomics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Assays and Kits
Instrument
Segmentation by application
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Agilent Technologies, Inc
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Fluidigm Corporation
General Electric Company
Illumina, Inc.
Merck KGaA
Myriad Genetics, Inc.
Pacific Biosciences of California, Inc.
PerkinElmer
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
LPI (LP Information)' newest research report, the “Tumor Genomics Industry Forecast” looks at past sales and reviews total world Tumor Genomics sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Genomics sales for 2023 through 2029. With Tumor Genomics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Genomics industry.
This Insight Report provides a comprehensive analysis of the global Tumor Genomics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Genomics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Genomics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Genomics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Genomics.
The global Tumor Genomics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Tumor Genomics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Tumor Genomics players cover Abbott Laboratories, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Fluidigm Corporation, General Electric Company, Illumina, Inc. and Merck KGaA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Genomics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Assays and Kits
Instrument
Segmentation by application
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Agilent Technologies, Inc
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Fluidigm Corporation
General Electric Company
Illumina, Inc.
Merck KGaA
Myriad Genetics, Inc.
Pacific Biosciences of California, Inc.
PerkinElmer
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Tumor Genomics Market Size 2018-2029
2.1.2 Tumor Genomics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Tumor Genomics Segment by Type
2.2.1 Assays and Kits
2.2.2 Instrument
2.3 Tumor Genomics Market Size by Type
2.3.1 Tumor Genomics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Tumor Genomics Market Size Market Share by Type (2018-2023)
2.4 Tumor Genomics Segment by Application
2.4.1 Diagnostics and Monitoring
2.4.2 Drug Discovery and Development
2.4.3 Biomarker Discovery
2.5 Tumor Genomics Market Size by Application
2.5.1 Tumor Genomics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Tumor Genomics Market Size Market Share by Application (2018-2023)
3 Tumor Genomics Market Size by Player
3.1 Tumor Genomics Market Size Market Share by Players
3.1.1 Global Tumor Genomics Revenue by Players (2018-2023)
3.1.2 Global Tumor Genomics Revenue Market Share by Players (2018-2023)
3.2 Global Tumor Genomics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Tumor Genomics by Regions
4.1 Tumor Genomics Market Size by Regions (2018-2023)
4.2 Americas Tumor Genomics Market Size Growth (2018-2023)
4.3 APAC Tumor Genomics Market Size Growth (2018-2023)
4.4 Europe Tumor Genomics Market Size Growth (2018-2023)
4.5 Middle East & Africa Tumor Genomics Market Size Growth (2018-2023)
5 Americas
5.1 Americas Tumor Genomics Market Size by Country (2018-2023)
5.2 Americas Tumor Genomics Market Size by Type (2018-2023)
5.3 Americas Tumor Genomics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Genomics Market Size by Region (2018-2023)
6.2 APAC Tumor Genomics Market Size by Type (2018-2023)
6.3 APAC Tumor Genomics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Tumor Genomics by Country (2018-2023)
7.2 Europe Tumor Genomics Market Size by Type (2018-2023)
7.3 Europe Tumor Genomics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Tumor Genomics by Region (2018-2023)
8.2 Middle East & Africa Tumor Genomics Market Size by Type (2018-2023)
8.3 Middle East & Africa Tumor Genomics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Tumor Genomics Market Forecast
10.1 Global Tumor Genomics Forecast by Regions (2024-2029)
10.1.1 Global Tumor Genomics Forecast by Regions (2024-2029)
10.1.2 Americas Tumor Genomics Forecast
10.1.3 APAC Tumor Genomics Forecast
10.1.4 Europe Tumor Genomics Forecast
10.1.5 Middle East & Africa Tumor Genomics Forecast
10.2 Americas Tumor Genomics Forecast by Country (2024-2029)
10.2.1 United States Tumor Genomics Market Forecast
10.2.2 Canada Tumor Genomics Market Forecast
10.2.3 Mexico Tumor Genomics Market Forecast
10.2.4 Brazil Tumor Genomics Market Forecast
10.3 APAC Tumor Genomics Forecast by Region (2024-2029)
10.3.1 China Tumor Genomics Market Forecast
10.3.2 Japan Tumor Genomics Market Forecast
10.3.3 Korea Tumor Genomics Market Forecast
10.3.4 Southeast Asia Tumor Genomics Market Forecast
10.3.5 India Tumor Genomics Market Forecast
10.3.6 Australia Tumor Genomics Market Forecast
10.4 Europe Tumor Genomics Forecast by Country (2024-2029)
10.4.1 Germany Tumor Genomics Market Forecast
10.4.2 France Tumor Genomics Market Forecast
10.4.3 UK Tumor Genomics Market Forecast
10.4.4 Italy Tumor Genomics Market Forecast
10.4.5 Russia Tumor Genomics Market Forecast
10.5 Middle East & Africa Tumor Genomics Forecast by Region (2024-2029)
10.5.1 Egypt Tumor Genomics Market Forecast
10.5.2 South Africa Tumor Genomics Market Forecast
10.5.3 Israel Tumor Genomics Market Forecast
10.5.4 Turkey Tumor Genomics Market Forecast
10.5.5 GCC Countries Tumor Genomics Market Forecast
10.6 Global Tumor Genomics Forecast by Type (2024-2029)
10.7 Global Tumor Genomics Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Information
11.1.2 Abbott Laboratories Tumor Genomics Product Offered
11.1.3 Abbott Laboratories Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Abbott Laboratories Main Business Overview
11.1.5 Abbott Laboratories Latest Developments
11.2 Agilent Technologies, Inc
11.2.1 Agilent Technologies, Inc Company Information
11.2.2 Agilent Technologies, Inc Tumor Genomics Product Offered
11.2.3 Agilent Technologies, Inc Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Agilent Technologies, Inc Main Business Overview
11.2.5 Agilent Technologies, Inc Latest Developments
11.3 Bio-Rad Laboratories, Inc.
11.3.1 Bio-Rad Laboratories, Inc. Company Information
11.3.2 Bio-Rad Laboratories, Inc. Tumor Genomics Product Offered
11.3.3 Bio-Rad Laboratories, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Bio-Rad Laboratories, Inc. Main Business Overview
11.3.5 Bio-Rad Laboratories, Inc. Latest Developments
11.4 Danaher Corporation
11.4.1 Danaher Corporation Company Information
11.4.2 Danaher Corporation Tumor Genomics Product Offered
11.4.3 Danaher Corporation Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Danaher Corporation Main Business Overview
11.4.5 Danaher Corporation Latest Developments
11.5 F. Hoffmann-La Roche Ltd
11.5.1 F. Hoffmann-La Roche Ltd Company Information
11.5.2 F. Hoffmann-La Roche Ltd Tumor Genomics Product Offered
11.5.3 F. Hoffmann-La Roche Ltd Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 F. Hoffmann-La Roche Ltd Main Business Overview
11.5.5 F. Hoffmann-La Roche Ltd Latest Developments
11.6 Fluidigm Corporation
11.6.1 Fluidigm Corporation Company Information
11.6.2 Fluidigm Corporation Tumor Genomics Product Offered
11.6.3 Fluidigm Corporation Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Fluidigm Corporation Main Business Overview
11.6.5 Fluidigm Corporation Latest Developments
11.7 General Electric Company
11.7.1 General Electric Company Company Information
11.7.2 General Electric Company Tumor Genomics Product Offered
11.7.3 General Electric Company Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 General Electric Company Main Business Overview
11.7.5 General Electric Company Latest Developments
11.8 Illumina, Inc.
11.8.1 Illumina, Inc. Company Information
11.8.2 Illumina, Inc. Tumor Genomics Product Offered
11.8.3 Illumina, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Illumina, Inc. Main Business Overview
11.8.5 Illumina, Inc. Latest Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Information
11.9.2 Merck KGaA Tumor Genomics Product Offered
11.9.3 Merck KGaA Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Merck KGaA Main Business Overview
11.9.5 Merck KGaA Latest Developments
11.10 Myriad Genetics, Inc.
11.10.1 Myriad Genetics, Inc. Company Information
11.10.2 Myriad Genetics, Inc. Tumor Genomics Product Offered
11.10.3 Myriad Genetics, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Myriad Genetics, Inc. Main Business Overview
11.10.5 Myriad Genetics, Inc. Latest Developments
11.11 Pacific Biosciences of California, Inc.
11.11.1 Pacific Biosciences of California, Inc. Company Information
11.11.2 Pacific Biosciences of California, Inc. Tumor Genomics Product Offered
11.11.3 Pacific Biosciences of California, Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Pacific Biosciences of California, Inc. Main Business Overview
11.11.5 Pacific Biosciences of California, Inc. Latest Developments
11.12 PerkinElmer
11.12.1 PerkinElmer Company Information
11.12.2 PerkinElmer Tumor Genomics Product Offered
11.12.3 PerkinElmer Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 PerkinElmer Main Business Overview
11.12.5 PerkinElmer Latest Developments
11.13 QIAGEN
11.13.1 QIAGEN Company Information
11.13.2 QIAGEN Tumor Genomics Product Offered
11.13.3 QIAGEN Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 QIAGEN Main Business Overview
11.13.5 QIAGEN Latest Developments
11.14 Siemens Healthineers AG
11.14.1 Siemens Healthineers AG Company Information
11.14.2 Siemens Healthineers AG Tumor Genomics Product Offered
11.14.3 Siemens Healthineers AG Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Siemens Healthineers AG Main Business Overview
11.14.5 Siemens Healthineers AG Latest Developments
11.15 Thermo Fisher Scientific Inc.
11.15.1 Thermo Fisher Scientific Inc. Company Information
11.15.2 Thermo Fisher Scientific Inc. Tumor Genomics Product Offered
11.15.3 Thermo Fisher Scientific Inc. Tumor Genomics Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Thermo Fisher Scientific Inc. Main Business Overview
11.15.5 Thermo Fisher Scientific Inc. Latest Developments
12 Research Findings and Conclusion